FFG
CRSP icon

Frisch Financial Group’s CRISPR Therapeutics CRSP Stock Holding History

Frisch Financial Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5,359
Closed -$261K – 159
2025
Q2 		$261K Buy
+5,359
New +$207K 0.06% 120
2021
Q3 		– Sell
-1,250
Closed -$202K – 151
2021
Q2 		$202K Buy
+1,250
New +$152K 0.06% 148

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Frisch Financial Group's CRSP Position: Q3 2025 in Review

Frisch Financial Group sold out of CRISPR Therapeutics (CRSP) in Q3 2025, closing a stake of 5,359 shares — an estimated $261K sold.

Frisch Financial Group first reported a position in CRSP in Q2 2021 and held it in 2 quarters. The position peaked at $261K in Q2 2025. 440 funds tracked by Wall St. Rank hold CRSP as of Q3 2025.

  • Frisch Financial Group reported no remaining CRISPR Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Frisch Financial Group sold 5,359 CRISPR Therapeutics shares in Q3 2025, an estimated $261K.
  • Frisch Financial Group first reported a position in CRISPR Therapeutics in Q2 2021 and held it in 2 quarters.
  • Frisch Financial Group's CRISPR Therapeutics position peaked at $261K in Q2 2025.
  • 440 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2025.

Based on Frisch Financial Group's 13F filing for Q3 2025, filed 10 Nov 2025.